Biodexa Secures Exclusive License for Novel Molecular Glue MTX240 to Target TKI-Resistant GIST
核心洞察
Biodexa Pharmaceuticals has obtained exclusive global licensing rights to OPB-171775 (MTX240 (搜索)) from Otsuka Pharmaceutical (搜索), a Phase 1-ready molecular glue compound designed to treat gastrointestinal stromal tumors (搜索).
MTX240 (搜索) employs a novel mechanism that brings PDE3a (搜索) and SLFN12 (搜索) proteins together to trigger apoptosis in GIST (搜索) cells, bypassing KIT (搜索) signaling pathways that cause resistance to current tyrosine kinase inhibitors.
Patient-derived xenograft studies demonstrated dose-dependent anti-tumor efficacy against imatinib and sunitinib resistant GIST (搜索) models, addressing the significant unmet need for 10-15% of patients who develop TKI resistance.
Biodexa Pharmaceuticals PLC announced on February 4, 2026, the completion of an exclusive licensing agreement with Otsuka Pharmaceutical (搜索) Co., Ltd for OPB-171775, a novel molecular glue compound now designated MTX240 (搜索) in Biodexa's pipeline. The Phase 1-ready therapeutic is being developed to treat gastrointestinal stromal tumors (搜索) (GIST (搜索)), with potential applications in additional indications.
"MTX240 (搜索) represents a fantastic opportunity for Biodexa. Its unique molecular glue mechanism of action separates MTX240 from current standard of care with the potential to benefit a broad spectrum of GIST (搜索) patients, including those with TKI-resistant disease," said Stephen Stamp, Chief Executive Officer of Biodexa. "MTX240 strategically aligns with our emerging GI/oncology pipeline which includes our ongoing Phase 3 development of eRapa in Familial Adenomatous Polyposis."
Novel Molecular Glue Mechanism Targets Treatment-Resistant Disease
MTX240 (搜索) represents a departure from conventional kinase inhibitor approaches through its molecular glue technology, which induces targeted protein interactions. The compound addresses a critical limitation in current GIST (搜索) treatment, where resistance to tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib almost always develops through secondary KIT (搜索) mutations or activation of alternative signaling pathways.
The drug acts by bringing two intracellular proteins, PDE3a (搜索) and SLFN12 (搜索), specifically co-expressed by GIST (搜索) cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT (搜索) signaling. By triggering cell death through this alternative pathway, MTX240 (搜索) is designed to overcome the resistance mechanisms that render TKI-resistant GISTs refractory to conventional kinase inhibitors.
Preclinical Efficacy in Resistant Models
Patient-derived xenograft (PDX) studies conducted by E.O. Takaki et al. demonstrated MTX240 (搜索)'s dose-dependent anti-tumor efficacy in imatinib and sunitinib resistant models, irrespective of KIT (搜索) mutation status. In the studies, MTX240 and vehicle were administered once daily for 21 days, while imatinib was administered twice daily for 21 days across multiple PDX models including GS5107 (n=3), GS5108 (n=5), and GS11353 (n=5).
PDX models use actual tumor tissue harvested from patients, preserving the genetic complexity and treatment resistance patterns of real human cancers, making these studies more predictive of human clinical outcomes by bridging the gap between laboratory discovery and clinical trials.
Addressing Significant Unmet Medical Need
GIST (搜索) affects approximately 3,000-4,000 patients annually in the United States, representing a rare gastrointestinal malignancy with substantial unmet medical need for patients who develop TKI resistance. Approximately 10-15% of GIST patients are either primarily refractory or develop secondary resistance to available TKIs, with limited therapeutic options remaining for these patients.
The global GIST (搜索) market is valued at approximately USD 1.3 billion and is expected to grow at 6-10% annually through 2032, driven by rising incidence and emerging therapeutic options targeting treatment-resistant disease. GIST qualifies for orphan drug designation in major regulatory jurisdictions, offering potential regulatory advantages and incentives to support drug development.
Licensing Terms and Patent Protection
Under the licensing agreement, Biodexa has secured exclusive rights to develop and commercialize MTX240 (搜索) globally, with the exception of Japan where Otsuka retains its rights. The agreement includes an upfront fee and additional development and regulatory milestones, along with tiered royalties in the mid-single digit range payable on net sales of MTX240.
MTX240 (搜索) benefits from composition of matter patents in the US, Europe, Japan and various other countries extending through 2037 without any patent term extension, providing substantial intellectual property protection for the compound's commercial development.